google-site-verification: googlec7193c3de77668c9.html

Monoclonal antibody shows promising results for rare liver disease

[
A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver disease called primary sclerosing cholangitis. Researchers learned that an anti-inflammatory and anti-fibrotic monoclonal antibody known as nebokitug was safe and showed potential efficacy in patients with PSC.


Source link

Advertisements
Views: 0

See also  Discovery about brain receptors may open the door to new Alzheimer's treatments

Check Also

Socioeconomic challenges color patients’ lung cancer screening experience

[ Credit: MART PRODUCTION from Pexels New research among lung cancer screening participants has found …

‘World-first’ vaccine designed by artificial intelligence

The trials, in 39 people, were designed to assess if such vaccines were safe. A …

NI health: Consultants and specialist doctors begin strike action

Dr David Farren, chair of BMA’s Northern Ireland consultants committee, said: “No doctor wants to …

Leave a Reply

Available for Amazon Prime
New wordpress website is being built and will be published soon. Just a moment....